Thomas Smith
Stock Analyst at Leerink Partners
(1.05)
# 3,504
Out of 4,758 analysts
70
Total ratings
29.03%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $2.33 | +286.27% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $1.82 | +284.62% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $5.10 | +468.63% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $17.85 | +118.49% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $3.65 | +612.33% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $10 | $1.12 | +792.86% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $8.29 | +141.25% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $613.18 | -29.06% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $55.50 | -35.14% | 1 | Feb 28, 2023 | |
| EQ Equillium | Maintains: Outperform | $12 → $7 | $0.79 | +786.08% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $0.83 | +743.37% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $19.52 | +7.58% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $15.88 | +183.38% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $4.29 | +39.86% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $4.92 | +21.95% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $1.15 | +334.78% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $39.82 | -57.31% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $21.33 | +200.05% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $18.22 | +284.19% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $8.31 | +248.98% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $3.81 | +582.41% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $13 → $12 | $0.25 | +4,646.84% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $28.68 | -58.16% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.39 | +194.99% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $4.14 | +9,561.84% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $11.93 | +570.58% | 2 | Dec 8, 2020 | |
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $2.33
Upside: +286.27%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.82
Upside: +284.62%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $5.10
Upside: +468.63%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $17.85
Upside: +118.49%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $3.65
Upside: +612.33%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $10
Current: $1.12
Upside: +792.86%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $8.29
Upside: +141.25%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $613.18
Upside: -29.06%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $55.50
Upside: -35.14%
Equillium
Feb 8, 2023
Maintains: Outperform
Price Target: $12 → $7
Current: $0.79
Upside: +786.08%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $0.83
Upside: +743.37%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $19.52
Upside: +7.58%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $15.88
Upside: +183.38%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $4.29
Upside: +39.86%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $4.92
Upside: +21.95%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $1.15
Upside: +334.78%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $39.82
Upside: -57.31%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $21.33
Upside: +200.05%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $18.22
Upside: +284.19%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $8.31
Upside: +248.98%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $3.81
Upside: +582.41%
May 12, 2022
Maintains: Market Perform
Price Target: $13 → $12
Current: $0.25
Upside: +4,646.84%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $28.68
Upside: -58.16%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.39
Upside: +194.99%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $4.14
Upside: +9,561.84%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $11.93
Upside: +570.58%